ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Acumen Pharmaceuticals (ABOS) pipeline and stated timing

Name in SEC filings: Acumen Pharmaceuticals, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
sabirnetug/data readoutStage not statedWording in the quote below8-K ·

Source: ORION, orionbiotechai.com/company/ABOS, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/ABOS

Latest retained statement: sabirnetug · Topline/data readout · Exact timing wording below · filed

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

sabirnetug

Early AD

Matched

Topline/data readoutExact timing wording below

Stage: Not stated

Public float: Unknown (no public float found in SEC filings).

ALTITUDE-AD topline results expected in late 2026, inclusive of efficacy, safety and biomarker data

8-K · Filed · Last checked

Source details

Accession 0001628280-26-062137

Alert me · Calendar: same stage

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

No additional verified wording history is retained.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained program pages

Watch ABOS

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ABOS. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ABOS in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.